Estradiol/Norethindrone Acetate Transdermal System shortage — NL supply status & alternatives

Estradiol/Norethindrone Acetate Transdermal System

—

In supply · Australia

Combipatch

In supply · 🇦🇺 Australia · short in🇳🇱 NL

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Estradiol/Norethindrone Acetate Transdermal System

Brand names	Combipatch

Therapeutic category	Auto-created by FDA Drug Enforcement — Full Recall Database scraper

Controlled substance	No

Marketing-authorisation holders	Noven Therapeutics, LLC

Registrations on file	2

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🇺🇸

COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM)

Noven Pharmaceuticals Inc · July 2021

Class IIdetails ↗

🇺🇸

COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM)

Noven Pharmaceuticals Inc · July 2021

Class IIdetails ↗

Verified timeline regulator events

🇳🇱 26 June 2026

medium reported

🇳🇱 5 June 2026

medium reported

🇳🇱 4 June 2026

high reported

🇳🇱 23 Mar 2026

medium reported

🇳🇱 9 Mar 2026

medium reported

🇳🇱 15 Dec 2025

medium reported

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
CombiPatch	.05; .14mg/d; mg/d	patch	🇺🇸 US	Noven Therapeutics, LLC	Active
CombiPatch	.05; .25mg/d; mg/d	patch	🇺🇸 US	Noven Therapeutics, LLC	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.